chufangao/CTO huggingface dataset:
Clinical trial NCT05099159: A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
Official title: A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 400.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-29
Primary completion date: 2023-06-13
Completion date: 2023-10-10
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Clinical trial NCT03743064: A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Official title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Helsinn Healthcare SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 318.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-06
Primary completion date: 2022-12-27
Completion date: 2022-12-27
Baseline population: The Intent-to-Treat (ITT) Set included all randomized patients and was analyzed as per planned treatment.
Clinical trial NCT05212701: To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess Efficacy and Safety of Reparixin in Cancer Related Fatigue in Pts With Advanced / Metastatic Breast Cancer Undergoing Taxane-based Chemotherapy.
Sponsor: Dompé Farmaceutici S.p.A (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Dompé decided to withdraw the study due to the numerous difficulties encountered in enrollment, mainly due to the rapidly and continuously changing oncology drug scenario . No patients were enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-19
Primary completion date: 2023-06-30
Completion date: 2024-07-31
Clinical trial NCT03809429: Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)
Official title: A Randomised, Controlled, Open Label, Parallel Group, Multicentre Trial Comparing the Efficacy and Safety of Individualised FE 999049 (Follitropin Delta) Dosing, Using a Long GnRH Agonist Protocol and a GnRH Antagonist Protocol in Women Undergoing Controlled Ovarian Stimulation
Acronym: BEYOND
Sponsor: Ferring Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 437.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-29
Primary completion date: 2022-02-16
Completion date: 2022-02-16
Plan to share individual participant data: NO
Clinical trial NCT04196010: Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
Official title: Dose-Finding (Phase 1) Study of Continuous Infusion Cladribine, Cytarabine and Mitoxantrone (CI-CLAM) for Adults With Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms Treated at UW/SCCA
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Terminated due to unfavorable risk-benefit ratio of investigational regimen.
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-08
Primary completion date: 2021-10-13
Completion date: 2021-10-13
Plan to share individual participant data: NO
Clinical trial NCT03445780: Comparison of Distraction Methods for Pain Relief of Trigger Finger Injection
Official title: Comparison of Distraction Methods for Pain Relief of Trigger Finger Injection
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No patients were enrolled; Senior author (Dr. Melamed) departed institution
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-06-30
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Clinical trial NCT02860494: Topical Everolimus in Patients With Tuberous Sclerosis Complex
Official title: Topical Everolimus Versus Placebo for the Treatment of Facial Angiofibromas in Patients With Tuberous Sclerosis Complex. A Phase II/III, Multicentre, Randomized, Double-blind, Placebo-controlled Study of 3 Doses of Topical Everolimus.
Acronym: EVEROST
Sponsor: Hospices Civils de Lyon (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Pharmaceutical and financial difficulties
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-12-31
Primary completion date: 2023-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT03991104: SOX-based CRT for Esophageal Cancer.
Official title: A Phase I/II Study of S-1 and Oxaliplatin Based Definitive Concurrent Chemoradiotherapy (SOX-CRT-01) for Unresectable Locally Advanced Esophageal Cancer.
Sponsor: Zhejiang Provincial People's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: No eligible patients enrolled. We have to withdraw the trial.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-01
Primary completion date: 2021-12-31
Completion date: 2023-12-31
Clinical trial NCT03082014: Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function
Official title: EffecTs of Amlodipine and Other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases
Acronym: TREAT-SVDs
Sponsor: Ludwig-Maximilians - University of Munich (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: completed for the primary study group of sporadic SVD patients, halted prematurely for the additional study group due to slow recruitment at 26 of 30 CADASIL patients in December 2022
Enrollment: 101.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-02-22
Primary completion date: 2022-07-28
Completion date: 2022-07-28
Plan to share individual participant data: NO
Clinical trial NCT04300309: Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
Official title: Multicenter, Open-label, Single-arm Study to Evaluate the PK, Safety, Tolerability and Efficacy of a New Artemether:Lumefantrine (2.5 mg:30 mg) Dispersible Tablet in the Treatment of Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
Acronym: CALINA
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 28.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-21
Primary completion date: 2023-07-02
Completion date: 2024-05-10
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT02043678: Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
Official title: A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)
Acronym: ERA 223
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 806.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-03-30
Primary completion date: 2018-02-15
Completion date: 2024-02-08
Baseline population: Intent-to-treat analysis set (ITT) included all randomized participants.
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Clinical trial NCT03840343: Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
Official title: Intra-arterially Delivered Autologous Mesenchymal Stem/Stromal Cell Therapy in Patients With Diabetic Kidney Disease: A Phase I Study
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Principal Investigator relocation
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-23
Primary completion date: 2020-08-04
Completion date: 2020-08-04
Plan to share individual participant data: NO
Clinical trial NCT03430479: Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
Official title: Phase Ib/II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
Sponsor: Kyoto Breast Cancer Research Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-22
Primary completion date: 2018-11-30
Completion date: 2021-04-01
Clinical trial NCT01093066: Prospective Multicentric Evaluation of a Bladder Preservation Strategy
Official title: Prospective Multicentric Evaluation of a Bladder Preservation Strategy Using a Combination of Neoadjuvant Chemotherapy and Optimal Bladder Transurethral Resection in Patients With a Urothelial Carcinoma
Acronym: ReChiVe
Sponsor: Centre Hospitalier Universitaire de Saint Etienne (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulties in the inclusion and follow-up of patients
Enrollment: 77.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2010-09-21
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT04845191: COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
Official title: Phase 1/2 Study of the Safety, Reactogenicity, and Immunogenicity of a Subcutaneously- and Orally- Administered Supplemental Spike & Nucleocapsid-targeted COVID-19 Vaccine to Enhance T Cell Based Immunogenicity in Participants Who Have Already Received Prime + Boost Vaccines Authorized For Emergency Use
Sponsor: ImmunityBio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: The sponsor has changed the development plans which is not for safety reasons.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-31
Primary completion date: 2022-03-31
Completion date: 2022-08-31
Clinical trial NCT03063190: Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease
Official title: Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome
Acronym: RLS
Sponsor: University of Sao Paulo General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: the main research is no longer in the Institution
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-03-31
Primary completion date: 2022-03-31
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT02736968: Auranofin for Giardia Protozoa
Official title: Phase IIa Randomized, Single-Blinded, Placebo-Controlled Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 93.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-11-06
Primary completion date: 2021-03-10
Completion date: 2021-03-10
Baseline population: No analyses performed on the following groups due to no participants enrolled: Asymptomatic E. histolytica- Auranofin, Symptomatic E. histolytica- Auranofin, Symptomatic E. histolytica- Placebo. Because only one participant was enrolled in Asymptomatic E. histolytica- Placebo, no analyses were performed.
Clinical trial NCT04433013: A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19
Official title: A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19
Sponsor: Nanyang Technological University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Unable to find suitable site Principal Investigator. This study did not start and was withdrawn as of Aug 2020 (have updated as of Sept 2020, please proceed to update the status of study withdrawal accordingly)
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-31
Primary completion date: 2020-12-31
Completion date: 2021-02-28
Plan to share individual participant data: NO
Clinical trial NCT04385667: LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia
Official title: The Efficacy of Levonorgestrel Intrauterine System Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia. A Randomized Controlled Trial.
Sponsor: Zagazig University (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 143.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-20
Primary completion date: 2022-12-01
Completion date: 2022-12-25
Plan to share individual participant data: NO
Clinical trial NCT05245916: IBI397 or Combination Therapies in Patients With Advanced Malignancies
Official title: A Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI397 or Combination Therapies in Patients With Advanced Malignancies
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Due to the company's development strategy adjustment
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-04-14
Primary completion date: 2023-08-24
Completion date: 2023-08-24
Clinical trial NCT02631603: Stop Exogenous Allergic Alveolitis (EAA) in Childhood
Official title: Stop Exogenous Allergic Alveolitis (EAA) in Childhood: Healthy Into Adulthood - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prednisolone Treatment and Course of Disease
Acronym: chILD-EU_EAA
Sponsor: Ludwig-Maximilians - University of Munich (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: funding pending
Enrollment: 45.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2015-04-30
Primary completion date: 2023-04-30
Completion date: 2024-04-30
Clinical trial NCT03935555: Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Official title: Phase 1b Study of PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Treated With Ruxolitinib
Sponsor: Samus Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Samus Therapeutics company closure
Enrollment: 11.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-08-12
Primary completion date: 2022-10-19
Completion date: 2022-11-04
Plan to share individual participant data: NO
Clinical trial NCT04549025: Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
Official title: Phase 2 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab, an ICOS Agonist, in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
Acronym: SELECT
Sponsor: Jounce Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The Sponsor decided to discontinue development of pimivalimab prior to the planned study completion. At the time of the decision to discontinue development, enrollment in the study had been completed.
Enrollment: 69.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-10-19
Primary completion date: 2024-04-25
Completion date: 2024-04-25
Clinical trial NCT02470065: Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.
Official title: Resectable EGFR Mutant NSCLC With (or Without) Afatinib as Neoadjuvant Treatment; REMNANT an Exploratory Study of the EORTC Lung Cancer Group
Acronym: REMNANT
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Study never started
Enrollment: 38.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2016-01-31
Primary completion date: 2018-09-30
Completion date: 2021-01-31
Clinical trial NCT02914561: Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
Official title: Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease
Acronym: DIVERSITY1
Sponsor: Galapagos NV (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1372.0 (ACTUAL)
Number of arms: 11.0
Start date: 2016-10-31
Primary completion date: 2022-11-11
Completion date: 2022-11-11
Baseline population: The All Randomized Analysis Set included all participants who were randomized in the study.
Plan to share individual participant data: NO
Clinical trial NCT04498377: Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
Sponsor: EVIVE Biotechnology (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: There have been significant changes in the FDA guidelines and clinical standard of care
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-26
Primary completion date: 2021-03-24
Completion date: 2021-03-24
Baseline population: This study enrolled only 1 patient in F-652 arm, no patient enrolled in placebo arm.
Plan to share individual participant data: NO
Clinical trial NCT03481634: Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Official title: A Two-year, Three-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema
Acronym: KESTREL
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 566.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-23
Primary completion date: 2020-11-11
Completion date: 2021-10-18
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT04807309: PRETELL: PREvention of TELomere-related Complications After Lung Transplant
Official title: PRETELL: PREvention of TELomere-related Complications After Lung Transplant
Acronym: PRETELL
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Lack of financial support
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-01
Primary completion date: 2021-11-20
Completion date: 2022-01-01
Plan to share individual participant data: NO
Clinical trial NCT04810494: Intranasal Lidocaine for Prevention of Postoperative Nausea and Vomiting.
Official title: Intranasal Lidocaine for Prevention of Postoperative Nausea and Vomiting. A Prospective Double Blind Randomized Controlled Study.
Sponsor: Milton S. Hershey Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Change in study team
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-01
Primary completion date: 2023-03-31
Completion date: 2023-06-30
Clinical trial NCT04835389: Study of AlloGen® Liquid Intra-articular Injection for Knee Osteoarthritis
Official title: A Phase 1 Study Evaluating the Safety and Preliminary Efficacy of AlloGen® Liquid Intra-articular Injection for Knee Osteoarthritis
Sponsor: VIVEX Biologics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Company decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-01
Primary completion date: 2022-03-01
Completion date: 2022-06-30
Plan to share individual participant data: NO